GRI Bio, Inc.

GRI Bio is advancing an innovative pipeline of Natural Killer T cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases. $GRI

[GRI Bio, Inc. @GRI_BIO]

At GRI Bio, we are exploring the potential of NKT cell biology to develop novel therapies for serious immune-mediated diseases.

With a growing pipeline and proprietary platform, we are working to bring new treatment options to patients in need.

$GRI #IdiopathicPulmonaryFibrosis

[GRI Bio, Inc. @GRI_BIO]

For 250 years, America has been shaped by curiosity, resilience and a belief in what's possible. Today, we celebrate that spirit and the communities that continue to move us forward.

Happy Fourth of July from all of us at GRI Bio.

#IndependenceDay

[GRI Bio, Inc. @GRI_BIO]

#IPF has a life-altering impact. Early diagnosis can make a real difference.

Learn more here: https://t.co/qW1ieg02x2

$GRI #FibroticDisease

[GRI Bio, Inc. @GRI_BIO]

Stay Connected!
Sign up for our email alerts to hear the latest on our progress.

https://t.co/OJrGPW354I

$GRI #IPF #FibroticDisease

[GRI Bio, Inc. @GRI_BIO]

The Orphan Drug Designation granted to GRI-0621 for the treatment of IPF represents a significant regulatory achievement and reinforces the growing recognition of the drug's potential to address significant unmet medical needs in fibrotic diseases. Learn more: https://t.co/SCklcarXPR $GRI

[GRI Bio, Inc. @GRI_BIO]

"Receiving FDA Orphan Drug Designation for GRI-0621 in IPF is an important validation of our development strategy and highlights the urgent need for innovative therapies capable of altering the course of this devastating disease," said Marc Hertz, PhD, Chief Executive Officer of GRI Bio. For more info: https://t.co/SCklcarXPR

[GRI Bio, Inc. @GRI_BIO]

GRI Bio announced the FDA has granted Orphan Drug Designation to GRI-0621 for the treatment of #IdiopathicPulmonaryFibrosis, highlighting a significant regulatory milestone that provides a potential pathway to seven years of U.S. market exclusivity. For details: https://t.co/SCklcarXPR $GRI

[GRI Bio, Inc. @GRI_BIO]

At GRI Bio, we are dedicated to advancing innovative therapies for inflammatory, fibrotic and autoimmune diseases.

Through science-driven approaches, we are working to address serious unmet medical needs and improve patient outcomes.

$GRI #IPF #FibroticDisease

[GRI Bio, Inc. @GRI_BIO]

Idiopathic Pulmonary Fibrosis remains a devastating disease, with 50% of patients dying within 2–3 years of diagnosis.

$GRI is focused on advancing an innovative solution for patients facing serious unmet needs in pulmonary disease.

#IPF #IdiopathicPulmonaryFibrosis

[GRI Bio, Inc. @GRI_BIO]

Stay connected with $GRI Bio!

Sign up to receive updates on our clinical progress, company news and developments:
https://t.co/OJrGPW354I

#IPF #InflammatoryDisease #FibroticDisease

[GRI Bio, Inc. @GRI_BIO]

IPF kills faster than many cancers.

Median survival:
• Prostate cancer: >15 years
• Breast cancer: 10–15 years
• IPF: 2–5 years
• Ovarian cancer: 2–4 years

IPF patients face a 4.7x higher risk of death, underscoring the urgent need for new therapeutic approaches.

$GRI

[GRI Bio, Inc. @GRI_BIO]

New Ph. 2a analyses from $GRI's GRI-0621-IPF-02 trial show zero cough, ~60% lower treatment-related diarrhea vs. placebo despite higher nintedanib use in the active arm – reinforcing GRI-0621's differentiated profile in #IdiopathicPulmonaryFibrosis. https://t.co/cEnZJqpCss

[GRI Bio, Inc. @GRI_BIO]

“The growing body of Phase 2a clinical, translational and biomarker data continues to reinforce GRI-0621’s differentiated therapeutic potential in #idiopathicpulmonaryfibrosis,” commented Marc Hertz, PhD, CEO of GRI Bio. For more info: https://t.co/cEnZJqpCss $GRI

[GRI Bio, Inc. @GRI_BIO]

GRI Bio today reported Q1 2026 financial results and provided a corporate update, highlighting new Ph. 2a data reinforcing the differentiated profile of GRI-0621 in #IdiopathicPulmonaryFibrosis and continued pipeline advancement. For details: https://t.co/cEnZJqpCss $GRI #IPF

[GRI Bio, Inc. @GRI_BIO]

On #WorldImmunologyDay, we recognize the power of the immune system and the importance of advancing science to better understand and treat immune-mediated diseases.

Learn more: https://t.co/8PTyoW6NHM

$GRI #IPF #AutoimmuneDisease #FibroticDisease

[GRI Bio, Inc. @GRI_BIO]

#InCaseYouMissedIt: A closer look at the IPF landscape and what’s next.

H.C. Wainwright’s Breath of Fresh Air KOL Call featured discussion of GRI Bio’s Phase 2a clinical data and its potential moving forward.

Watch the replay now: https://t.co/aDPGjm3mbR
$GRI

[GRI Bio, Inc. @GRI_BIO]

Meet our management team and discover more about the leaders shaping our mission.

https://t.co/1DOukrEbUh

$GRI #IPF #FibroticDisease #AutoimmuneDisease #InflammatoryDisease

[GRI Bio, Inc. @GRI_BIO]

We believe in our differentiated approach to treating inflammatory, fibrotic and autoimmune diseases, and remain focused on advancing our programs to address areas of significant unmet medical need.

$GRI #FibroticDisease #AutoimmuneDisease #IPF #InfammatoryDisease

[GRI Bio, Inc. @GRI_BIO]

Marc Hertz, PhD, CEO of GRI Bio, comments on the Company's UAE Notice of Allowance, reflecting continued execution of GRI Bio's disciplined global IP strategy and expanding the Company's strategic presence in a key high-growth international market. https://t.co/E6SSQTrEVO $GRI

[GRI Bio, Inc. @GRI_BIO]

GRI Bio announced a Notice of Allowance from the United Arab Emirates Patent Office for UAE Patent No. P6000687/2017, covering novel type 2 diverse NKT cell agonists for the prevention and treatment of inflammatory conditions, further expanding its global IP portfolio. For details: https://t.co/CpUGYW4ttu $GRI